Steven Prestrelski
Founder bei XERIS BIOPHARMA HOLDINGS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Steven Prestrelski is the founder of Xeris Pharmaceuticals, Inc. (founded in 2005) and Xeris Biopharma Holdings, Inc. (founded in 2005) where he held the title of Chief Scientific Officer.
He also held former positions as Executive Director at BaroFold, Inc., VP-Pharmaceutical Research & Development at Amylin Pharmaceuticals, Inc. (from 2005 to 2011), and Vice President-Biopharmaceuticals at Powderject Technologies, Inc. (from 1998 to 2002).
Dr. Prestrelski earned a doctorate degree from City University of New York in 1990 and an MBA degree from Rady School of Management at UC San Diego in 2006.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.01.2023 | 719 780 ( 0,51% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Steven Prestrelski
| Unternehmen | Position | Beginn |
|---|---|---|
| XERIS BIOPHARMA HOLDINGS, INC. | Founder | 01.01.2005 |
Ehemalige bekannte Positionen von Steven Prestrelski
| Unternehmen | Position | Ende |
|---|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.01.2011 |
| Powderject Technologies, Inc. | Corporate Officer/Principal | 01.03.2002 |
BaroFold, Inc.
 BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Director/Board Member | - |
Xeris Pharmaceuticals, Inc.
 Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | Founder | - |
Ausbildung von Steven Prestrelski
| City University of New York | Doctorate Degree |
| Rady School of Management at UC San Diego | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
BaroFold, Inc.
BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Health Technology |
Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xeris Pharmaceuticals, Inc. operates as a pharmaceutical company. It develops and commercializes ready-to-use, liquid-stable injectables. The firm offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL. | Health Technology |
| Powderject Technologies, Inc. | |
| Xeris Biopharma Holdings, Inc. |
